Last reviewed · How we verify
Standard Dose Colistin
Colistin disrupts bacterial cell membranes by binding to lipopolysaccharides and phospholipids, causing cell lysis and death.
Colistin disrupts bacterial cell membranes by binding to lipopolysaccharides and phospholipids, causing cell lysis and death. Used for Multidrug-resistant gram-negative bacterial infections (e.g., Pseudomonas aeruginosa, Acinetobacter baumannii), Hospital-acquired pneumonia caused by susceptible gram-negative organisms, Urinary tract infections caused by resistant gram-negative bacteria.
At a glance
| Generic name | Standard Dose Colistin |
|---|---|
| Also known as | Colistin |
| Sponsor | King Saud Medical City |
| Drug class | Polymyxin antibiotic |
| Target | Bacterial lipopolysaccharides and phospholipids |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease |
| Phase | FDA-approved |
Mechanism of action
Colistin is a polymyxin antibiotic that acts as a cationic detergent, inserting into the outer and inner membranes of gram-negative bacteria. This disrupts membrane integrity and leads to leakage of cellular contents and bacterial cell death. It is primarily used against multidrug-resistant gram-negative organisms when other antibiotics have failed.
Approved indications
- Multidrug-resistant gram-negative bacterial infections (e.g., Pseudomonas aeruginosa, Acinetobacter baumannii)
- Hospital-acquired pneumonia caused by susceptible gram-negative organisms
- Urinary tract infections caused by resistant gram-negative bacteria
Common side effects
- Nephrotoxicity (acute kidney injury)
- Neurotoxicity (paresthesias, dizziness, vertigo)
- Neuromuscular blockade
- Injection site reactions
Key clinical trials
- Perioperative SDD to Prevent Infectious Complications After Esophagectomy (PHASE3)
- Mortality of MBL-producing Enterobacteriaceae Bacteremias with the Combined Use of Ceftazidime-avibactam and Aztreonam Vs. Other Active Antibiotics. a Multicenter Target Trial Emulation.
- Selective Decontamination of the Digestive Tract in Intensive Care Unit Patients (PHASE3)
- Dose Optimization by Pharmacokinetic/Pharmacodynamic of Antibiotics to Improve Clinical Outcome of Carbapenem Resistant Klebsiella Pneumoniae Bloodstream Infections in Critically Ill Patients at Phramongkutklao Hospital (PHASE4)
- IV Colistin for Pulmonary Exacerbations: Improving Safety and Efficacy (PHASE4)
- Trial for the Treatment of Extensively Drug-Resistant Gram-negative Bacilli (OVERCOME) (PHASE3)
- Randomized-controlled Trial (RCT) on Combination Antibiotic for Infections Caused by Gram-negative Bacteria (PHASE2, PHASE3)
- Does Administration of Antibiotics in Patients Undergoing Surgery for Colorectal Cancer Result in Less Complications and Better Prognosis? (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Standard Dose Colistin CI brief — competitive landscape report
- Standard Dose Colistin updates RSS · CI watch RSS
- King Saud Medical City portfolio CI